241 related articles for article (PubMed ID: 32886753)
21. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
22. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.
Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR
Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500
[TBL] [Abstract][Full Text] [Related]
23. Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study.
Xu M; Shu J; Qian S; Guo J; Gong Y; Huang R; Wang S; Zhou Z; Yuan G; Huang M; Lin LE; Lou S; Song Y; Liu Q; Zhou H; Mei H; Hu Y
Lancet Reg Health West Pac; 2024 Jun; 47():101096. PubMed ID: 38808021
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
25. A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
Chen Y; Xu Y; Li H; Sun T; Cao X; Wang Y; Xue F; Liu W; Liu X; Dong H; Fu R; Dai X; Wang W; Ma Y; Song Z; Chi Y; Ju M; Gu W; Pei X; Yang R; Zhang L
N Engl J Med; 2024 Jun; 390(23):2178-2190. PubMed ID: 38899695
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
Lledo-Garcia R; Dixon K; Shock A; Oliver R
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):116-128. PubMed ID: 34735735
[TBL] [Abstract][Full Text] [Related]
27. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura.
van der Lugt NM; van Kampen A; Walther FJ; Brand A; Lopriore E
Vox Sang; 2013 Oct; 105(3):236-43. PubMed ID: 23782272
[TBL] [Abstract][Full Text] [Related]
28. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
[TBL] [Abstract][Full Text] [Related]
30. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
31. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
DasGupta RK; Levine L; Wiczer T; Cataland S
J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
[TBL] [Abstract][Full Text] [Related]
32. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
33. Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.
Han B; Kim HJ; Yhim HY; Oh D; Bae SH; Shin HJ; Lee WS; Kwon J; Lee JO; Kim HJ; Bang SM
Ann Hematol; 2022 Jul; 101(7):1435-1445. PubMed ID: 35643952
[TBL] [Abstract][Full Text] [Related]
34. Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP.
Gil Gonzalez L; Won KD; Tawhidi Z; Cummins E; Cruz-Leal Y; Tundidor Cabado Y; Sachs UJ; Norris PAA; Shan Y; Bhakta V; Li J; Samudio I; Silva-Moreno B; Cerna-Portillo L; Pavon Oro A; Bergqvist P; Chan P; Moorehead A; Sholzberg M; Sheffield WP; Lazarus AH
Blood Adv; 2024 Apr; 8(8):1869-1879. PubMed ID: 38330193
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.
Heitink-Pollé KMJ; Uiterwaal CSPM; Porcelijn L; Tamminga RYJ; Smiers FJ; van Woerden NL; Wesseling J; Vidarsson G; Laarhoven AG; de Haas M; Bruin MCA;
Blood; 2018 Aug; 132(9):883-891. PubMed ID: 29945954
[TBL] [Abstract][Full Text] [Related]
36. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.
Teeling JL; Jansen-Hendriks T; Kuijpers TW; de Haas M; van de Winkel JG; Hack CE; Bleeker WK
Blood; 2001 Aug; 98(4):1095-9. PubMed ID: 11493456
[TBL] [Abstract][Full Text] [Related]
38. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial.
Qi J; Zheng L; Hu B; Zhou H; He Q; Liu H; Kawai H; Yang R
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):379-387. PubMed ID: 34921514
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a new intravenous immunoglobulin (Panzyga
Arbach O; Taumberger AB; Wietek S; Cervinek L; Salama A
Transfus Med; 2019 Feb; 29(1):48-54. PubMed ID: 30687970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
